We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

LGC Clinical Diagnostics

LGC Clinical Diagnostics is a leading provider of Quality Measurement Tools, biological materials, and reagents for t... read more Featured Products: More products

Download Mobile App





LGC Clinical Diagnostics Presents Seraseq and ACCURUN Range of Diagnostic Solutions

By LabMedica International staff writers
Posted on 12 Nov 2024

LGC Clinical Diagnostics (Middlesex, UK) is presenting its latest diagnostic solutions at this year’s MEDICA, including Seraseq and ACCURUN, which align with the increasing demand for personalized medicine and enhance clinical research capabilities, along with other best-in-class products across the company’s portfolio. More...

At MEDICA 2024, LGC is providing full access to its product brands including Technopath Clinical Diagnostics (IVD raw materials, independent quality controls, QC software solutions), SeraCare (quality controls, reference materials, biological materials, research), Biochemical Diagnostics (drugs of abuse testing), KOVA International (urinalysis controls), Maine Standards (linearity and calibration verification, calibrators, OEM PT/EQA samples), and The Native Antigen Company (viral and bacterial antigens & antibodies, reagent components).

LGC is highlighting SeraCare’s comprehensive suite of patient-like reference materials that accelerates development, streamlines validation, and ensures confidence in the results of today’s demanding clinical genomics assays. These platform-agnostic, ground-truth reference materials can be used through all development phases to verify actionable and challenging variants as well as complex genomic signatures in patient samples. These ready-to-use reference materials cover clinically relevant variants and all variant types - SNVs, INDELS, CNVs, and RNA fusions. Highly multiplexed, they provide significantly more data per NGS run, saving sequencing costs. They are also available in multiple formats to suit different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA in plasma, and FFPE.

LGC is also presenting SeraCare’s ACCURUN molecular controls and reference materials which are whole-cell or whole-organism external controls that help monitor all aspects of molecular testing methods and provide additional confidence in laboratory test results. A well-designed QC program can help labs avoid costly false-negative or false-positive results. ACCURUN molecular controls effectively detect low-positives closer to assay-specific cutoffs, enabling better detection of assay variability. The powerful ACCURUN controls and reference materials help to ensure complete control over assay performance monitoring.

Related Links:
LGC


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.